Lunch Symposium (II)
Treatment for HER2 Positive Metastatic Gastric Cancer
13:00 - 13:40, L & B Cafe (醫圖咖啡廳)
Abstract - Treatment for HER2 positive metastatic gastric cancer
The prevalence of HER2 overexpression in gastric cancer is around 7-34%. The presence of HER2 overexpression is both a prognostic and a predictive factor for patients with advanced gastric adenocarcinoma. Although trastuzumab combined with chemotherapy in first line has been proved to improve the progression-free survival and overall survival for patients with metastatic gastric cancer in ToGA trial, several important issues remain: how to optimize the detection of HER2 overexpression, what the other anti-HER2 therapies are, the emergence of resistance to anti-HER2 therapy, and future prospective. In this symposium, we will discuss these clinically relevant questions.